nach oben

Current Pulmonology Reports

Erschienen in:

29.10.2018 | Interstitial Lung Disease (A. Hajari Case, Section Editor)

Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis

verfasst von: Giuliana Pasciuto, Riccardo Inchingolo, Carola Condoluci, Daniele Magnini, Bruno Iovene, Luca Richeldi

Erschienen in: Current Pulmonology Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Treatment of idiopathic pulmonary fibrosis (IPF) shifted significantly in the past few years, in the light of advances in understanding pathological pathways. The promising results coming from recent trials led to a growing number of studies dealing with IPF. The purpose of this article is to review scientific evidences supporting approved therapies and to provide an overview of experimental treatments that are currently under investigation.

Recent Findings

Approved anti-fibrotic treatments are based on large randomized trials showing the efficacy of pirfenidone and nintedanib in slowing IPF progression with an acceptable tolerability. However, we are still far from a definite cure and research efforts are focused on exploring new therapeutic targets and alternative treatment strategies.

Summary

Although pirfenidone and nintedanib remain the mainstay of IPF treatment, novel therapies are under investigation in clinical trials. Combination therapy will probably be a successful key for the future, targeting multiple pathways simultaneously.

Clinical Registration

NCT01619085

• Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68 This international, evidence-based guideline provides an update on the diagnosis of IPF. CrossRef

Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.CrossRef

• Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–e19 This guideline provides recommendations for or against specific agents based on literature evidences; nintedanid and pirfenidone received for the first time a conditional recommandation for the treatment in IPF patients. CrossRef

Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-B-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–9.CrossRef

Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367–73.PubMed

Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, et al. Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts. Life Sci. 2008;82:210–7.CrossRef

Meyer KC, Decker CA. Role of pirfenidone in the management of pulmonary fibrosis. Ther Clin Risk Manag. 2017;13:427–37.CrossRef

Kim ES, Keating GM. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs 2015.

Spagnolo P, Maher TM, Richeldi L. Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol. Ther. [Internet] Elsevier Inc. 2015;152:18–27. https://doi.org/10.1016/j.pharmthera.2015.04.005.CrossRef

10.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. [Internet] 2017; 26Available from: https://doi.org/10.1183/16000617.0057-2017.CrossRef

11.

Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017;22:1171–8.CrossRef

12.

Margaritopoulos GA, Vasarmidi E, Antoniou KM. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid. [Internet]. 2016;11:11–22 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27445644%5Cn http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4936814.CrossRef

13.

Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–9.CrossRef

14.

• Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9 This study supported the use of pirfenidone in the treatment of IPF.CrossRef

15.

• King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med BioMed Central. 2014;370:2083–92 This study confirmed the efficacy of pirfenidone in reducing disease progression in IPF, leading to its approval by the FDA. CrossRef

16.

Lancaster L, Albera C, Bradford WZ, Costabel U, Du Bois RM, Fagan EA, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Resp Res [Internet]. 2016;3. https://doi.org/10.1136/bmjresp-2015-000105.CrossRef

17.

Noble PW, Albera C, Bradford WZ, Costabel U, Du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J [Internet]. 2016, 47:243–53. https://doi.org/10.1183/13993003.00026-2015.CrossRef

18.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax [Internet]. 2016;71:429–35. https://doi.org/10.1136/thoraxjnl-2015-207011.CrossRef

19.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5:33–41.CrossRef

20.

Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016.

21.

Robalo-Cordeiro C, Campos P, Carvalho L, Borba A, Clemente S, Freitas S, Furtado S, Jesus JM, Leal C, Marques A, Melo N, Souto-Moura C, Neves S, Sousa V, Santos A, Morais A. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence. Rev Port Pneumol (English Ed. 2017; 23: 287–293.CrossRef

22.

Costabel U, Albera C, Lancaster LH, Lin C-Y, Hormel P, Hulter HN, et al. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration [Internet]. 2017:408–15. https://doi.org/10.1159/000479976.CrossRef

23.

Koschel D, Cottin V, Skold M, Tomassetti S, Azuma A, Giot C, et al. Pirfenidone post-authorization safety registry (PASSPORT) – interim analysis of IPF treatment. Eur Respir J. 2014;44.

24.

Mazzei ME, Richeldi L, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2015;9:121–9.CrossRef

25.

Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, et al. Nintedanib: from discovery to the clinic. J Med Chem [Internet]. 2015;58:1053–63 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25474320.CrossRef

26.

Sun L, Tran N, Tang F, App H, Hirth P, McMahon G, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 1998;41:2588–603.CrossRef

27.

Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–82.CrossRef

28.

Roth GJ, Heckel A, Colbatzky F, Handschuh S, Kley J, Lehmann-Lintz T, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009;52:4466–80.CrossRef

29.

Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov Nat Publ Group. 2010;9:956–70.CrossRef

30.

Fukihara J, Kondoh Y. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med [Internet]. 2016;10:1247–54 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27744713.CrossRef

31.

Varone F, Sgalla G, Iovene B, Bruni T, Richeldi L. Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother [Internet]. 2018;19:167–75 Available from: http://www.tandfonline.com/action/journalInformation?journalCode=ieop20.CrossRef

32.

Dallinger C, Trommeshauser D, Marzin K, Liesener A, Kaiser R, Stopfer P. Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. J Clin Pharmacol [Internet]. 2016;56:1387–94 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27093880.CrossRef

33.

Stopfer P, Rathgen K, Bischoff D, Lüdtke S, Marzin K, Kaiser R, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. [Internet]. 2011;41:297–311 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21204634.CrossRef

34.

• Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med [Internet]. 2011;365:1079–87 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21992121. This study supported the efficacy and safety of nintedanib in the treatment of IPF. CrossRef

35.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. INPULSIS Trial InvestigatorsEfficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med [Internet]. 2014;370:2071–82 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24836310.

36.

Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med [Internet]. 2016;193:178–85 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26393389.CrossRef

37.

Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax [Internet] McMaster University, Hamilton, Ontario, Canada. National Institute for Health Research Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, University of Southampton, Southampton, UK. Medizinische Klinik und Poliklinik; 2017; 72: 340–346Available from: http://www.ncbi.nlm.nih.gov/pubmed/27672117.CrossRef

38.

Azuma A, Taniguchi H, Inoue Y, Kondoh Y, Ogura T, Homma S, Fujimoto T, Sakamoto W, Sugiyama Y, Nukiwa T. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: a subgroup analysis of the INPULSIS® randomized trials. Respirology [Internet] John Wiley & Sons, Ltd; 2017; 22: 750–757Available from: https://doi.org/10.1111/resp.12960.CrossRef

39.

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med [Internet]. 2016;113:74–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26915984.CrossRef

40.

Crestani B, Quaresma M, Kaye M, Stansen W, Stowasser S, Kreuter M. Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS®-ON. 1.5 Diffus. Parenchymal Lung Dis. [Internet] European Respiratory Society; 2016. p. OA4960Available from: https://doi.org/10.1183/13993003.congress-2016.OA4960.

41.

Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. Lung [Internet] Springer; 2016; 194: 739–743 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27377558.CrossRef

42.

Mazzei ME, Richeldi L, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis [Internet]. 2015;9:121–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25862013.CrossRef

43.

Cottin V. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. Expert Opin Drug Saf [Internet]. 2017 [cited 2017 Jun 15];16:857–65. https://doi.org/10.1080/14740338.2017.1338268.CrossRef

44.

Inchingolo R, Condoluci C, Smargiassi A, Mastrobattista A, Boccabella C, Comes A, Golfi N, Richeldi L. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? Expert Opin. Pharmacother. [Internet] Taylor & Francis; 2017; 00: 1–12 Available from: https://doi.org/10.1080/14656566.2017.1383382.CrossRef

45.

Pilling D, Roife D, Wang M, Ronkainen SD, Crawford JR, Travis EL, et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol [Internet]. 2007 [cited 2018 May 20];179:4035–44 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17785842.CrossRef

46.

Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol [Internet]. 2011 [cited 2018 May 20];43:154–62 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21044893.CrossRef

47.

Murray LA, Rosada R, Moreira AP, Joshi A, Kramer MS, Hesson DP, Argentieri RL, Mathai S, Gulati M, Herzog EL, Hogaboam CM, Serum Amyloid P Therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. Feghali-Bostwick C, editor. PLoS One [Internet] 2010 [cited 2018 May 20]; 5: e9683Available from: http://www.ncbi.nlm.nih.gov/pubmed/20300636.

48.

Dillingh MR, van den Blink B, Moerland M, van Dongen MGJ, Levi M, Kleinjan A, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther [Internet]. 2013 [cited 2018 May 20];26:672–6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23380438.CrossRef

49.

van den Blink B, Dillingh MR, Ginns LC, Morrison LD, Moerland M, Wijsenbeek M, et al. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur Respir J [Internet] European Respiratory Society. 2016 [cited 2018 May 20];47:889–97 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26869678.CrossRef

50.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA [Internet] American Medical Association. 2018 [cited 2018 Aug 21];319:2299–307 Available from: https://jamanetwork.com/journals/jama/article-abstract/2681945.CrossRef

51.

Leask A, Parapuram SK, Shi-wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal [Internet]. 2009 [cited 2018 May 20];3:89–94 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19156539.CrossRef

52.

Bonniaud P, Martin G, Margetts PJ, Ask K, Robertson J, Gauldie J, et al. Connective tissue growth factor is crucial to inducing a profibrotic environment in “fibrosis-resistant” Balb/c mouse lungs. Am J Respir Cell Mol Biol [Internet] American Thoracic Society. 2004 [cited 2018 May 20], 31:510–6. https://doi.org/10.1165/rcmb.2004-0158OC.CrossRef

53.

Wang X, Wu G, Gou L, Liu Z, Wang X, Fan X, et al. A novel single-chain-Fv antibody against connective tissue growth factor attenuates bleomycin-induced pulmonary fibrosis in mice. Respirology [Internet] Wiley/Blackwell (10.1111). 2011 [cited 2018 May 20];16:500–7. https://doi.org/10.1111/j.1440-1843.2011.01938.x.CrossRef

54.

Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein–related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol [Internet] American Thoracic SocietyNew York, NY. 1999 [cited 2018 May 20];21:693–700. https://doi.org/10.1165/ajrcmb.21.6.3719.CrossRef

55.

Raghu G, Scholand MB, de Andrade J, Lancaster L, Mageto Y, Goldin J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J [Internet] European Respiratory Society. 2016 [cited 2018 May 20];47:1481–91 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26965296.CrossRef

56.

Gorina E, Richeldi L, Raghu G, Fernandez Perez E, Costabel U, Albera C, Lederer D, Flaherty K, Ettinger N, Bercz P, Singh B, Perez R, Goldin J, Kouchakji E, Porter S. PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients. Diffus Parenchymal Lung Dis. [Internet] European Respiratory Society; 2017 [cited 2018 May 20]. p. OA3400 Available from: https://doi.org/10.1183/1393003.congress-2017.OA3400.

57.

Gorina E, Goldin J, Hyun KG, Zhong M, Sekayan T, Yu P , Kouchakji E. Lung fibrosis measured by quantitative high resolution computed tomography (qHRCT) in idiopathic pulmonary fibrosis (IPF) patients treated with pamrevlumab (FG-3019). 2018; Available from: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A7688.

58.

Parker J, Sawtell R, Gagnon L, Hagerimania A, Laurin P, Kolb M, et al. PBI-4050 is safe and well tolerated and shows evidence of benefit in idiopathic pulmonary fibrosis. Am J Crit Care Med. 2017;195:A7606.

59.

Saini G, Porte J, Weinreb PH, Violette SM, Wallace WA, McKeever TM, et al. αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur Respir J [Internet] European Respiratory Society. 2015 [cited 2018 May 22];46:486–94 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25745053.CrossRef

60.

Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med [Internet] American Thoracic Society. 2008 [cited 2018 May 22];177:56–65. https://doi.org/10.1164/rccm.200706-805OC.CrossRef

61.

Maden CH, Fairman D, Chalker M, Costa MJ, Fahy WA, Garman N, et al. Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants. Eur J Clin Pharmacol [Internet] Springer. 2018 [cited 2018 May 22];74:701–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29532104.CrossRef

62.

Black KE, Berdyshev E, Bain G, Castelino F V, Shea BS, Probst CK, Fontaine BA, Bronova I, Goulet L, Lagares D, Ahluwalia N, Knipe RS, Natarajan V, Tager AM. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. [Internet] The Federation of American Societies for Experimental Biology; 2016 [cited 2018 May 22]; 30: 2435–2450 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27006447.

63.

Desroy N, Housseman C, Bock X, Joncour A, Bienvenu N, Cherel L, Labeguere V, Rondet E, Peixoto C, Grassot J-M, Picolet O, Annoot D, Triballeau N, Monjardet A, Wakselman E, Roncoroni V, Le Tallec S, Blanque R, Cottereaux C, Vandervoort N, Christophe T, Mollat P, Lamers M, Auberval M, Hrvacic B, Ralic J, Oste L, van der Aar E, Brys R, Heckmann B. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2- a ]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a first-in-class autotaxin inhibitor undergoing clinical evaluation for the treatment of idiopathic pulmonary fibrosis. J Med Chem. [Internet] 2017 [cited 2018 May 22]; 60: 3580–3590Available from: http://www.ncbi.nlm.nih.gov/pubmed/28414242.CrossRef

64.

Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. [Internet] 2017 [cited 2018 May 21]. 5:22–32 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27939076.CrossRef

65.

Furuie H, Yamasaki H, Suga M, Ando M. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J. 1997;10:787–94.PubMed

66.

Jakubzick C, Choi ES, Kunkel SL, Evanoff H, Martinez FJ, Puri RK, et al. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J Clin Pathol. 2004;57:477–86.CrossRef

67.

Parker JM, Glaspole IN, Lancaster LH, Haddad TJ, She D, Roseti SL, Fiening JP, Grant EP, Kell CM, Flaherty KR. A Phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. [Internet] 2017; : 201704–201784 Available from: https://doi.org/10.1164/rccm.201704-0784OC%0A http://www.ncbi.nlm.nih.gov/pubmed/28787186.CrossRef

68.

Jones MG, Sgalla G, Richeldi L. Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med [Internet] 2018; 197: 9–10 Available from: https://doi.org/10.1164/rccm.201708-1666ED.CrossRef

69.

Swigris JJ, Ogura T, Scholand M, Glaspole I, Maher TM, Kardatzke D, Kaminski J. The RIFF Study ( Cohort A ): A phase II , randomized , double-blind , placebo-controlled Trial of lebrikizumab as monotherapy in patients with idiopathic pulmonary fibrosis. 2018; Available from:https://doi.org/10.1164/ajrccm conference.2018.197.1_MeetingAbstracts.A6167.

70.

Maher TM, Kondoh Y, Corte TJ, Glassberg MK, Costabel U, Lancaster LH. The RIFF Study ( Cohort B ): A phase II , randomized , double-blind , placebo-controlled trial of lebrikizumab in combination with pirfenidone in patients with idiopathic pulmonary fibrosis. 2018; Available from: https://doi.org/10.1164/ajrccm conference.2018.197.1_MeetingAbstracts.A6168.

71.

Raghu G, Richeldi L, Crestani B, Wung P, Bejuit R, Esperet C, Soubrane C. Safety and efficacy of SAR156597 in idiopathic pulmonary fibrosis ( IPF ): a phase 2 , randomized, double-blind , placebo-controlled study. 2018; Available from: https://doi.org/10.1164/ajrccm conference.2018.197.1_MeetingAbstracts.A2441.

72.

Todd NW, Scheraga RG, Galvin JR, Iacono AT, James Britt E, Luzina IG, et al. Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res. 2013;6:63–70.CrossRef

73.

Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013;107:249–55.CrossRef

74.

Shum AK, Alimohammadi M, Tan CL, Cheng MH, Metzger TC, Law CS, et al. BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease. Sci Transl Med. 2013;5:206ra139.CrossRef

75.

Li FJ, Surolia R, Li H, Wang Z, Kulkarni T, Liu G, et al. Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis. J Immunol [Internet]. 2017;199:1596–605. https://doi.org/10.4049/jimmunol.1700473.CrossRef

76.

Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med. 2013;187:768–75.CrossRef

77.

Keir GJ, Maher TM, Ming D, Abdullah R, De Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353–9.CrossRef

78.

Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med [Internet]. 2007;357:1841–54 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17978293.CrossRef

79.

Yokomizo T, Izumi T, Shimizu T. Leukotriene B4: metabolism and signal transduction. Arch. Biochem. Biophys. 2001. p. 231–241.CrossRef

80.

Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989;84:19–26.CrossRef

81.

Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest [Internet]. 1996;97:1827–36 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8621765%5Cn http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC507250.CrossRef

82.

Izumo T, Kondo M, Nagai A. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci. 2007;80:1882–6.CrossRef

83.

Shimbori C, Shiota N, Okunishi H. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol. 2011;650:424–30.CrossRef

84.

Wilkes DS, Chew T, Flaherty KR, Frye S, Gibson KF, Kaminski N, et al. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1393–402.CrossRef

85.

Roskoski R. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 2015;94:9–25.CrossRef

86.

Yilmaz O, Oztay F, Kayalar O. Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice. Growth Factors. 2015;33:366–75.CrossRef

87.

Cruz FF, Horta LFB, De Albuquerque ML, Lopes-Pacheco M, Da Silva AB, Morales MM, et al. Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis. PLoS One. 2016;11:1–17.

88.

Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, Yerkovich ST, Khalil D, Atkinson KM, Hopkins PMA. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology 2014; .

89.

Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, et al. Prospective , non-randomized , no placebo-controlled , phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med. 2013;11:1.CrossRef

90.

Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, Difede D, Shafazand S, Khan A, Pujol M V., LaRussa VF, Lancaster LH, Rosen GD, Fishman J, Mageto YN, Mendizabal A, Hare JM. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I, safety, clinical trial. Chest 2016; .

91.

Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22:376–81.CrossRef

92.

Egan JJ, Adamali HI, Lok SS, Stewart JP, Woodcock AA. Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study. Pulm Med. 2011;2011:240805.CrossRef

93.

Molyneaux PL, Cox MJ, Willis-Owen SAG, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190:906–13.CrossRef

94.

Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson ECF, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68:884–5.CrossRef

Titel: Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis
verfasst von: Giuliana Pasciuto
Riccardo Inchingolo
Carola Condoluci
Daniele Magnini
Bruno Iovene
Luca Richeldi
Publikationsdatum: 29.10.2018
Verlag: Springer US
Erschienen in: Current Pulmonology Reports / Ausgabe 4/2018
Elektronische ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-018-0209-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis

Abstract

Purpose of Review

Recent Findings

Summary

Clinical Registration

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Clinical Registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Early Graft Dysfunction After Lung Transplantation

Assessment of Symptoms in Patients with COPD: Strengths and Limitations of Clinical Scores

The Diagnostic Approach to Interstitial Lung Disease

Nonpharmacological Therapies for Interstitial Lung Disease

Connective Tissue Related Interstitial Lung Disease

Chronic Lung Allograft Dysfunction

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Update Innere Medizin